Contact | Juniper Passage

Juniper Passage Home About Services Colorado Policy Guide Safety & Considerations Research Pilot Tracker Contact Field notes / Colorado Ibogaine Treatment Colorado A plainspoken guide to decriminalization, research access, regulation, and safety context in a state where the legal picture is still changing. The essential distinction Not an open clinic system. Colorado is now the most important U.S. state to watch on ibogaine because it has paired decriminalization with a new state research pilot program that could become the first U.S. pathway toward regulated, clinician-supervised access. But ibogaine is still federally Schedule I, so real treatment access in Colorado remains contingent on federal authorization and state rulemaking, not a fully open clinic system. Ibogaine is a psychoactive alkaloid derived from the iboga shrub native to Central Africa. Its basic history and pharmacology are summarized in the ibogaine overview , while Colorado policy discussions usually frame it around potential treatment for opioid use disorder, other substance use disorders, and PTSD alongside serious cardiac and medical risks. “Decriminalized” does not mean “clinically legal.” For Colorado, the topic separates into personal possession and cultivation for adults 21 and older, research access through the new pilot program, and possible regulated therapeutic access under the Natural Medicine Act framework. A recent Colorado policy argument captures why those categories need to stay distinct. Three buckets / one unsettled landscape Why 2026 matters Colorado has become a leading U.S. testing ground for whether ibogaine can move from controversial underground use to regulated medical research and possibly later to licensed treatment. The state may be the first to build an ibogaine research-to-regulation pipeline. Lawmakers and advocates are explicitly tying ibogaine to opioid addiction, PTSD, and veterans’ treatment needs. The federal scheduling question remains decisive: the DEA’s